Larson Financial Group LLC Lowers Position in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Larson Financial Group LLC trimmed its stake in SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report) by 26.3% in the third quarter, Holdings Channel.com reports. The firm owned 1,435 shares of the exchange traded fund’s stock after selling 513 shares during the quarter. Larson Financial Group LLC’s holdings in SPDR S&P Biotech ETF were worth $105,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of XBI. Bank Julius Baer & Co. Ltd Zurich boosted its stake in shares of SPDR S&P Biotech ETF by 100,996.9% in the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 601,188,701 shares of the exchange traded fund’s stock valued at $50,018,900,000 after purchasing an additional 600,594,035 shares during the period. JPMorgan Chase & Co. raised its holdings in SPDR S&P Biotech ETF by 179.1% in the first quarter. JPMorgan Chase & Co. now owns 7,534,471 shares of the exchange traded fund’s stock valued at $574,202,000 after acquiring an additional 4,835,071 shares in the last quarter. Jane Street Group LLC raised its holdings in SPDR S&P Biotech ETF by 315.1% in the first quarter. Jane Street Group LLC now owns 1,529,813 shares of the exchange traded fund’s stock valued at $116,587,000 after acquiring an additional 1,161,234 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in SPDR S&P Biotech ETF in the third quarter valued at $102,900,000. Finally, Alaska Permanent Fund Corp acquired a new stake in SPDR S&P Biotech ETF in the second quarter valued at $112,104,000.

SPDR S&P Biotech ETF Price Performance

XBI traded down $0.02 during trading on Friday, hitting $88.48. The company had a trading volume of 4,962,781 shares, compared to its average volume of 11,616,966. The company has a market cap of $6.79 billion, a PE ratio of 11.47 and a beta of 0.97. The business has a 50-day moving average of $83.99 and a 200-day moving average of $78.65. SPDR S&P Biotech ETF has a 1-year low of $63.80 and a 1-year high of $94.32.

SPDR S&P Biotech ETF Profile

(Free Report)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Read More

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.